Results 11 to 20 of about 4,644,977 (251)

Anti-VEGF therapy and retinopathy of prematurity [PDF]

open access: yes, 2023
Introduction:Nowadays, anti-vascular endothelial growth factor (VEGF) therapy is widely used as first-line therapy for retinopathy of prematurity (ROP) with very good therapeutic and visual results.Aim:The aim of the present study is to compare the ...
Manolova, Yana; Medical University of Varna   +1 more
core   +1 more source

Use of Ranibizumab for evaluating focal laser combination therapy for refractory diabetic macular edema patients: an exploratory study on the RELAND trials

open access: yesScientific Reports, 2023
Anti-vascular endothelial growth factor (VEGF) therapy is the first-line treatment for diabetic macular edema (DME), but is less effective in some patients.
Makoto Hatano   +9 more
doaj   +1 more source

Comparison of Intravitreal Anti-VEGF Agents With Laser Photocoagulation for Retinopathy of Prematurity of 1,627 Eyes in China

open access: yesFrontiers in Medicine, 2022
PurposeTo compare the efficacies and treatment outcomes of intravitreal anti-VEGF agents and laser therapy in retinopathy of prematurity (ROP).MethodsA retrospective, non-randomized, comparative study of patients diagnosed with type 1 ROP or aggressive ...
Dandan Linghu   +27 more
doaj   +1 more source

Navigated laser in diabetic macular edema: the impact of reduced injection burden on patients and physicians-who wins and who loses? [PDF]

open access: yesInternational Journal of Ophthalmology, 2019
We inquired the impact of reduced therapy discontinuation in diabetic macular edema (DME) on physician’s revenue considering anti-vascular endothelial growth factor (VEGF) monotherapy and its combination with Navilas treatment.
Jacob Menzler   +2 more
doaj   +1 more source

Characteristics of Eyes Developing Retinal Detachment After Anti-vascular Endothelial Growth Factor Therapy for Retinopathy of Prematurity

open access: yesFrontiers in Pediatrics, 2022
BackgroundWe investigated the incidence and clinical characteristics of eyes showing retinal detachment (RD) after anti-vascular endothelial growth factor (VEGF) for retinopathy of prematurity (ROP).MethodsA retrospective chart review of 76 consecutive ...
Chiori Kondo   +7 more
doaj   +1 more source

Immunoreactivity of the anti-VEGF-A121 and anti-VEGF-A165 monoclonal antibodies.

open access: yes, 2023
Mixture of rhVEGF-A121, rhVEGF-A165 and rhVEGF-A189 (50 μg each) were subjected to 15% SDS Polyacrylamide Gel Electrophoresis (SDS-PAGE). The transferred membrane was detected with anti-VEGF-A polyclonal antibody (left panel), anti-VEGF-A165 monoclonal ...
Yoko Oyama (600027)   +16 more
core   +1 more source

Supplementary Data from sFRP2 Supersedes VEGF as an Age-related Driver of Angiogenesis in Melanoma, Affecting Response to Anti-VEGF Therapy in Older Patients

open access: yes, 2020
Supplementary Data from sFRP2 Supersedes VEGF as an Age-related Driver of Angiogenesis in Melanoma, Affecting Response to Anti-VEGF Therapy in Older ...
Richard Colling (3185706)   +18 more
core   +7 more sources

Systematic review with network meta-analysis of antivascular endothelial growth factor use in managing polypoidal choroidal vasculopathy

open access: yesScientific Reports, 2021
Polypoidal choroidal vasculopathy (PCV) is a vision-threatening disease common in Asian populations. However, the optimal treatment for PCV remains under debate. We searched the databases with optimal searching strategy.
Sheng-Chu Chi, Yi-No Kang, Yi-Ming Huang
doaj   +1 more source

Evaluation of Anti-VEGF and Pan-Retinal Photocoagulation Laser Therapies in Proliferative Diabetic Retinopathy Patients: A Systematic Review

open access: yesPharmaceutical Sciences and Research, 2023
Diabetic retinopathy is a complication of diabetes that is one of the top five causes of blindness in those over 50. The standard treatment is pan-retinal photocoagulation, which is effective but has established side effects.
Senyum Indrakila   +4 more
doaj   +1 more source

CD63-mediated cloaking of VEGF in small extracellular vesicles contributes to anti-VEGF therapy resistance

open access: yes, 2021
Despite wide use of anti-vascular endothelial growth factor (VEGF) therapy for many solid cancers, most individuals become resistant to this therapy, leading to disease progression.
Bayaktar, Emine   +47 more
core   +1 more source

Home - About - Disclaimer - Privacy